Ipca Laboratories Limited
NSE: IPCALAB BSE: IPCALAB
NSE
1,450.20
10.30 (0.72%)
Prev Close
1439.9
Open Price
1470
Volume
22,979
Today Low / High
1443 / 1470
52 WK Low / High
1168.2 / 1595
Range
1,378 - 1,523
BSE
1,448.25
8.45 (0.59%)
Prev Close
1439.80005
Open Price
1454.55005
Volume
2,968
Today Low / High
1444 / 1473.8
52 WK Low / High
1200 / 1594.55
Range
1,376 - 1,521
The stock is currently trading on both the National Stock Exchange (NSE) and Bombay Stock Exchange (BSE). On the NSE, the stock is priced at 1450.2 (target range: 1,378 - 1,523), reflecting a change of 10.3 (0.71533%). On the BSE, it is listed at 1448.25 (target range: 1,376 - 1,521), showing a change of 8.44995 (0.58688%). Both the NSE and BSE data indicate positive movement, suggesting the stock is on an upward trend. This could be an attractive opportunity for investors looking for growth.
02 Feb
1,409.00
2.19%
01 Feb
1,467.80
-4.35%
30 Jan
1,479.70
-0.60%
29 Jan
1,448.10
2.18%
28 Jan
1,457.30
-0.70%
27 Jan
1,467.90
-0.89%
23 Jan
1,493.00
-2.02%
22 Jan
1,491.00
-0.36%
21 Jan
1,479.70
0.08%
20 Jan
1,475.00
0.32%
19 Jan
1,509.90
-1.50%
16 Jan
1,512.00
-0.14%
14 Jan
1,500.00
1.13%
13 Jan
1,529.80
-1.44%
12 Jan
1,574.00
-2.94%
09 Jan
1,545.00
1.94%
08 Jan
1,523.50
1.35%
07 Jan
1,475.50
2.62%
06 Jan
1,419.50
3.53%
Ipca Laboratories Limited Graph
Ipca Laboratories Limited Price Target Predictions: Bullish vs. Bearish Scenarios with Ranges
If you are looking for the target price for Ipca Laboratories Limited T1, T2, T3 for both Bullish and Bearish scenarios, here it is. For Bullish: T1, T2, T3. For Bearish: T1, T2, T3. The stock current price is 1,450.20, with potential price targets ranging from T1, T2, and T3 in both directions based on market conditions.
| Scenario | Price | Target | Range |
|---|---|---|---|
| Bullish Scenario | 1,448.25 | 1,462.73 | 1,316.46 - 1,609.01 |
| 1,477.22 | 1,181.77 - 1,772.66 | ||
| 1,491.70 | 1,044.19 - 1,939.21 | ||
| Bearish Scenario | 1,448.25 | 1,433.77 | 1,290.39 - 1,577.14 |
| 1,419.29 | 1,135.43 - 1,703.14 | ||
| 1,404.80 | 983.36 - 1,826.24 |
Overview of Ipca Laboratories Limited
ISIN
INE571A01038
Industry
Drug Manufacturers - Specialty & Generic
Vol.Avg
302,182
Market Cap
367,668,152,726
Last Dividend
4
Official Website
IPO Date
1996-01-01
DCF Diff
-2,912.47
DCF
4,371
Financial Ratios Every Investor Needs
Stock Dividend of IPCALAB
| Date | Label | Adj Dividend | Dividend | Record Date | Payment Date | Declaration Date |
|---|---|---|---|---|---|---|
| 2025-08-05 | August 05, 25 | 2 | 2 | 2025-08-05 | 2025-09-10 | |
| 2024-11-27 | November 27, 24 | 2 | 2 | 2024-11-27 | 2024-12-10 | |
| 2024-08-06 | August 06, 24 | 2 | 2 | 2024-08-06 | 2024-09-10 | |
| 2023-11-22 | November 22, 23 | 2 | 2 | 2023-11-22 | 2023-12-10 | |
| 2022-11-22 | November 22, 22 | 4 | 4 | 2022-11-23 | 2022-12-07 |
Annual Financial Income Report
| Date | Revenue | Co.Rev | GP | GPR | R&D Expenses | G&A Expenses | Operating Income | Net Income | EPS | EBITDA | NIR |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025-03-31 | 8,941.22 Cr | 3,081.45 Cr | 5,859.77 Cr | 0.6554 | 186.78 Cr | 0.00 Cr | 3,666.34 Cr | 737.68 Cr | 29.08 | 1,666.75 Cr | 0.0825 |
| 2024-03-31 | 7,705.88 Cr | 2,847.47 Cr | 4,858.41 Cr | 0.6305 | 165.47 Cr | 0.00 Cr | 2,960.86 Cr | 547.35 Cr | 21.57 | 1,264.39 Cr | 0.0710 |
| 2023-03-31 | 6,248.11 Cr | 2,522.93 Cr | 3,725.18 Cr | 0.5962 | 149.50 Cr | 0.00 Cr | 2,265.49 Cr | 471.32 Cr | 18.58 | 946.04 Cr | 0.0754 |
| 2022-03-31 | 5,830.50 Cr | 2,207.98 Cr | 3,622.52 Cr | 0.6213 | 135.37 Cr | 0.00 Cr | 2,289.91 Cr | 884.08 Cr | 34.85 | 1,274.89 Cr | 0.1516 |
| 2021-03-31 | 5,420.73 Cr | 1,896.49 Cr | 3,524.24 Cr | 0.6501 | 139.06 Cr | 0.00 Cr | 2,353.35 Cr | 1,140.01 Cr | 45.01 | 1,507.31 Cr | 0.2103 |
Annual Financials Balance Sheet
| Date | C&C Equ. | Tot. Assets | Tot. Liab. | Stock. Equity | Tot. Debt | Net Debt | Inv. | PP&E (Net) | Curr. Def. Rev. | Non-Curr. Def. Rev. | LT Invest. | Curr. Liab. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025-03-31 | 167.17 Cr | 11,760.55 Cr | 3,372.28 Cr | 6,948.4500 Cr | 1,362.74 Cr | 1,018.51 Cr | 2,560.42 Cr | 4,685.34 Cr | 0.00 Cr | 0.00 Cr | 275.40 Cr | 2,386.2200 Cr |
| 2024-03-31 | 208.91 Cr | 11,101.28 Cr | 3,374.28 Cr | 6,332.1900 Cr | 1,438.36 Cr | 1,229.45 Cr | 2,469.56 Cr | 4,696.18 Cr | 16.87 Cr | 0.12 Cr | 411.18 Cr | 2,355.6400 Cr |
| 2023-03-31 | 1,257.85 Cr | 8,626.43 Cr | 2,711.11 Cr | 5,842.0200 Cr | 1,481.27 Cr | 223.42 Cr | 1,743.37 Cr | 2,694.58 Cr | 27.40 Cr | 0.28 Cr | 302.66 Cr | 1,805.8200 Cr |
| 2022-03-31 | 275.19 Cr | 7,623.53 Cr | 2,081.77 Cr | 5,491.8700 Cr | 807.22 Cr | 532.03 Cr | 1,857.97 Cr | 2,502.59 Cr | 26.77 Cr | 0.54 Cr | 354.22 Cr | 1,465.8800 Cr |
| 2021-03-31 | 165.97 Cr | 6,068.36 Cr | 1,352.18 Cr | 4,701.6500 Cr | 265.39 Cr | 99.42 Cr | 1,594.81 Cr | 2,146.45 Cr | 20.85 Cr | 0.59 Cr | -480.24 Cr | 1,160.5400 Cr |
Annual Financials Cash Flow Statement
| Date | Operating Cash | Investing Cash | Financing Cash | Free Cash | Cash Change | Cash at End | CapEx | Income | Debt Repay | Dividends | Inventory |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025-03-31 | 1,275.1000 Cr | -893.5000 Cr | -212.7600 Cr | 499.5300 Cr | -41.9700 Cr | 169.7400 Cr | -775.5700 Cr | 737.6800 Cr | -93.2500 Cr | -101.4800 Cr | -91.5600 Cr |
| 2024-03-31 | 944.6500 Cr | -1,291.7900 Cr | -552.5500 Cr | 533.3600 Cr | -823.1900 Cr | 755.7900 Cr | -410.6000 Cr | 547.3500 Cr | -356.8800 Cr | -50.7400 Cr | -92.9500 Cr |
| 2023-03-31 | 805.8100 Cr | -725.0000 Cr | 507.2400 Cr | 311.3400 Cr | 588.0500 Cr | 1,578.9800 Cr | -494.4700 Cr | 745.2900 Cr | 657.7100 Cr | -101.4800 Cr | 114.6000 Cr |
| 2022-03-31 | 856.0400 Cr | -855.0500 Cr | 426.7800 Cr | 377.1200 Cr | 431.9200 Cr | 990.9300 Cr | -478.9500 Cr | 1,135.7200 Cr | 540.3200 Cr | -101.4800 Cr | -249.1500 Cr |
| 2021-03-31 | 1,090.1300 Cr | -520.6900 Cr | -305.8200 Cr | 728.5800 Cr | 263.6200 Cr | 559.0100 Cr | -361.5500 Cr | 1,381.2800 Cr | -225.7900 Cr | -101.5300 Cr | -271.6900 Cr |
Quarterly Financial Income Report
| Date | Revenue | Co.Rev | GP | GPR | Operating Income | Net Income | EPS | EBITDA | NIR |
|---|---|---|---|---|---|---|---|---|---|
| 2025-09-30 | 2,556.50 Cr | 781.64 Cr | 1,774.86 Cr | 0.6943 | 441.59 Cr | 282.57 Cr | 11.14 | 514.52 Cr | 0.1105 |
| 2025-06-30 | 2,308.85 Cr | 691.56 Cr | 1,617.29 Cr | 0.7005 | 1,074.12 Cr | 233.21 Cr | 9.19 | 408.73 Cr | 0.1010 |
| 2025-03-31 | 2,248.32 Cr | 1,011.19 Cr | 1,237.13 Cr | 0.5502 | 526.85 Cr | 67.82 Cr | 2.67 | 390.07 Cr | 0.0302 |
| 2024-12-31 | 2,245.37 Cr | 668.21 Cr | 1,577.16 Cr | 0.7024 | 1,091.72 Cr | 248.14 Cr | 9.78 | 447.82 Cr | 0.1105 |
| 2024-09-30 | 2,354.90 Cr | 758.56 Cr | 1,596.34 Cr | 0.6779 | 1,086.50 Cr | 229.48 Cr | 9.05 | 440.75 Cr | 0.0974 |
Quarterly Financials Balance Sheet
| Date | Cash & Equiv. | Short-Term Inv. | Cash & Short-Term | Net Receivables | Inventory | Total Curr. Assets | PP&E (Net) | Total Assets | Total Liabilities |
|---|---|---|---|---|---|---|---|---|---|
| 2025-09-30 | 212.95 Cr | 1,069.95 Cr | 1,282.90 Cr | 2,128.40 Cr | 2,515.87 Cr | 6,251.86 Cr | 4,944.76 Cr | 12,262.66 Cr | 3,396.84 Cr |
| 2025-06-30 | 0.00 Cr | 0.00 Cr | 1,105.05 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | -8,388.27 Cr |
| 2025-03-31 | 167.17 Cr | 937.88 Cr | 1,107.62 Cr | 1,916.58 Cr | 2,560.42 Cr | 5,967.04 Cr | 4,685.34 Cr | 11,760.55 Cr | 3,372.28 Cr |
| 2024-12-31 | 0.00 Cr | 0.00 Cr | 903.23 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | -8,117.66 Cr |
| 2024-09-30 | 297.04 Cr | 606.19 Cr | 903.23 Cr | 1,855.15 Cr | 2,518.31 Cr | 5,680.69 Cr | 4,776.43 Cr | 11,423.77 Cr | 3,306.11 Cr |
Quarterly Financials Cash Flow Statement
| Date | Net Income | Operating Cash Flow | Investing Cash Flow | Financing Cash Flow | Net Cash Change | Cash at End | Cash at Beginning | CapEx | Free Cash Flow |
|---|---|---|---|---|---|---|---|---|---|
| 2025-06-30 | 233.21 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr |
| 2025-03-31 | 67.82 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr |
| 2024-12-31 | 248.14 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr |
| 2024-09-30 | 229.48 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr |
| 2024-06-30 | 192.24 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr |
Splits History
| Date | Label | Split Ratio |
|---|---|---|
| 2022-01-10 | January 10, 22 | 2:1 |
| 2010-03-22 | March 22, 10 | 5:1 |
| 2005-01-28 | January 28, 05 | 2:1 |
Similar Stocks: Drug Manufacturers - Specialty & Generic
| Company Name | Symbol | Price | Market Cap | Volume |
|---|---|---|---|---|
| Sun Pharmaceutical Industries Limited | SUNPHARMA | ₹1,682.70 | ₹4,037,360,954,019.00 | ₹2,175,122.00 |
| Divi's Laboratories Limited | DIVISLAB | ₹6,244.50 | ₹1,657,718,547,810.00 | ₹98,152.00 |
| Torrent Pharmaceuticals Limited | TORNTPHARM | ₹4,042.00 | ₹1,367,996,468,480.00 | ₹159,874.00 |
| Dr. Reddy's Laboratories Limited | DRREDDY | ₹1,224.00 | ₹1,019,063,464,560.00 | ₹528,921.00 |
| Lupin Limited | LUPIN | ₹2,169.00 | ₹990,797,031,000.00 | ₹204,948.00 |
| Zydus Lifesciences Limited | ZYDUSLIFE | ₹900.35 | ₹905,962,772,897.00 | ₹271,538.00 |
| Mankind Pharma Limited | MANKIND | ₹2,122.90 | ₹876,343,887,349.00 | ₹63,792.00 |
| Aurobindo Pharma Limited | AUROPHARMA | ₹1,230.40 | ₹714,618,316,939.00 | ₹978,482.00 |
| Alkem Laboratories Limited | ALKEM | ₹5,667.50 | ₹677,634,637,500.00 | ₹34,484.00 |
| Glenmark Pharmaceuticals Limited | GLENMARK | ₹1,964.00 | ₹554,242,388,876.00 | ₹162,495.00 |
| Laurus Labs Limited | LAURUSLABS | ₹981.65 | ₹529,950,213,720.00 | ₹735,288.00 |
| Suven Pharmaceuticals Limited | SUVENPHAR | ₹1,078.00 | ₹412,407,234,624.00 | ₹1,177,218.00 |
| Ipca Laboratories Limited | IPCALAB | ₹1,450.20 | ₹367,921,856,944.00 | ₹22,979.00 |
| Ajanta Pharma Limited | AJANTPHARM | ₹2,793.20 | ₹348,970,184,957.00 | ₹14,592.00 |
| J. B. Chemicals & Pharmaceuticals Limited | JBCHEPHARM | ₹1,896.40 | ₹304,248,934,000.00 | ₹55,916.00 |
| Emcure Pharmaceuticals Ltd. | EMCURE | ₹1,514.10 | ₹287,031,782,814.00 | ₹46,641.00 |
| Piramal Enterprises Limited | PEL | ₹1,124.20 | ₹254,856,250,172.00 | ₹2,148,582.00 |
| Wockhardt Limited | WOCKPHARMA | ₹1,359.00 | ₹220,826,857,671.00 | ₹314,141.00 |
| AstraZeneca Pharma India Limited | ASTRAZEN | ₹8,670.50 | ₹216,762,500,000.00 | ₹3,564.00 |
| Eris Lifesciences Limited | ERIS | ₹1,423.60 | ₹193,918,366,028.00 | ₹40,260.00 |
| Neuland Laboratories Limited | NEULANDLAB | ₹13,510.00 | ₹173,331,800,390.00 | ₹33,838.00 |
| Jubilant Pharmova Limited | JUBLPHARMA | ₹989.10 | ₹156,643,517,747.00 | ₹39,283.00 |
| Alembic Pharmaceuticals Limited | APLLTD | ₹789.85 | ₹155,255,383,491.00 | ₹36,998.00 |
| NATCO Pharma Limited | NATCOPHARM | ₹848.30 | ₹151,938,902,721.00 | ₹280,562.00 |
| Cohance Lifesciences Limited | COHANCE | ₹384.50 | ₹147,097,065,330.00 | ₹110,639.00 |
| Caplin Point Laboratories Limited | CAPLIPOINT | ₹1,841.60 | ₹139,983,139,354.00 | ₹33,193.00 |
| Granules India Limited | GRANULES | ₹567.25 | ₹137,653,829,151.00 | ₹190,121.00 |
| Glenmark Life Sciences Limited | GLS | ₹1,086.00 | ₹133,070,838,000.00 | ₹130,938.00 |
| Alivus Life Sciences Ltd. | ALIVUS | ₹946.40 | ₹116,157,350,400.00 | ₹28,498.00 |
| Viyash Scientific Limited | VIYASH | ₹214.98 | ₹93,775,471,074.00 | ₹766,380.00 |
| Procter & Gamble Health Limited | PGHL | ₹5,247.00 | ₹87,096,957,354.00 | ₹9,080.00 |
| Strides Pharma Science Limited | STAR | ₹852.40 | ₹78,568,023,257.00 | ₹112,827.00 |
| Aarti Pharmalabs Limited | AARTIPHARM | ₹785.50 | ₹71,203,449,437.00 | ₹51,323.00 |
| Akums Drugs & Pharmaceuticals Ltd. | AKUMS | ₹445.80 | ₹68,252,897,456.00 | ₹28,558.00 |
| FDC Limited | FDC | ₹380.50 | ₹61,949,236,962.00 | ₹42,113.00 |
| Shilpa Medicare Limited | SHILPAMED | ₹297.35 | ₹58,156,252,988.00 | ₹194,189.00 |
| Sequent Scientific Limited | SEQUENT | ₹202.40 | ₹50,564,340,966.00 | ₹13,647.00 |
| Sun Pharma Advanced Research Company Limited | SPARC | ₹139.17 | ₹45,163,669,402.00 | ₹1,180,523.00 |
| Innova Captab Limited | INNOVACAP | ₹728.45 | ₹41,685,499,530.00 | ₹27,907.00 |
| Aarti Drugs Limited | AARTIDRUGS | ₹397.55 | ₹36,284,388,500.00 | ₹90,829.00 |
| Gujarat Themis Biosyn Ltd. | GUJTHEM | ₹325.30 | ₹35,446,400,705.00 | ₹46,236.00 |
| Orchid Pharma Limited | ORCHPHARMA | ₹674.65 | ₹34,217,644,188.00 | ₹24,730.00 |
| Suven Life Sciences Limited | SUVEN | ₹142.85 | ₹32,494,660,900.00 | ₹92,987.00 |
| RPG Life Sciences Limited | RPGLIFE | ₹1,963.50 | ₹32,474,355,953.00 | ₹9,519.00 |
| Gufic Biosciences Limited | GUFICBIO | ₹302.00 | ₹30,285,316,812.00 | ₹34,224.00 |
| Unichem Laboratories Limited | UNICHEMLAB | ₹396.05 | ₹27,884,197,288.00 | ₹19,688.00 |
Key Executives
President of R&D - Chemicals
Ashok Kumar
Gender: Not Specified
Year Born: 1954
Chief Financial Officer, MD & Executive Director
Ajit Kumar Bhanwarlal Jain
Gender: male
Year Born: 1955
Chief Financial Officer, MD & Executive Director
Pranay Godha
Gender: male
Year Born: 1972
Compliance Officer, Corporate Counsel & Company Secretary
Harish Kamath
Gender: male
Year Born: 1959
Vice President of Operations
Pawan Kothari
Gender: male
Year Born: 1965
Executive Director
Prashant Premchand Godha
Gender: male
Year Born: 1974
Executive Chairman
Premchand Godha A.
Gender: male
Year Born: 1947
President of Human Resources
Saidutta Nanda
Gender: male
Year Born:
President of Marketing
Sunil Ghai
Gender: male
Year Born: 1963
Vice President of Technical
Vishnu Saran Singh Kushwaha
Gender: male
Year Born: 1968
FAQs about Ipca Laboratories Limited
Who is the CEO of the company?
The CEO is Pranay Premchand Godha.
What is the current market price of the stock?
The current price is ₹1,449.20.
What is the 52-week price range?
The range is ₹1168.2-1595.
What is the market capitalization of the company?
The market capitalization is ₹36,766.82 crores.
What is the dividend yield?
The dividend yield is 0.28%.
What is the Price-to-Earnings (P/E) ratio?
The P/E ratio is 44.20.
Which sector does the company belong to?
The company operates in the Healthcare sector.
What does the company do?
Overview of Ipca Laboratories Limited (ISIN: INE571A01038) is a leading Drug Manufacturers - Specialty & Generic in India. With a market capitalization of ₹36,766.82 crores and an average daily volume of 302,182 shares, it operates in the Drug Manufacturers - Specialty & Generic. The company last declared a dividend of ₹4.